Bagsværd, Denmark and Singapore, 16 October 2023 “ Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension...
Novo Nordisk in $1.3 bln deal to buy hypertension drug
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease